Εμφάνιση απλής εγγραφής

dc.creatorLiaskos C., Marou E., Simopoulou T., Gkoutzourelas A., Barmakoudi M., Efthymiou G., Scheper T., Meyer W., Katsiari C.G., Bogdanos D.P., Sakkas L.I.en
dc.date.accessioned2023-01-31T08:55:06Z
dc.date.available2023-01-31T08:55:06Z
dc.date.issued2018
dc.identifier10.31138/mjr.29.3.120
dc.identifier.issn24593516
dc.identifier.urihttp://hdl.handle.net/11615/75907
dc.description.abstractBackground: Systemic sclerosis (SSc) is an autoimmune rheumatic disease characterized by a wide range of disease-specific and disease-related autoantibodies (autoAbs). Profile assays have been developed and are currently in use to meet the demand for better characterization of all autoAbs found in SSc patients. Aim: To assess the clinical relevance of SSc-related autoantibodies in 158 patients with SSc, all from Central Greece, taking advantage of a multiparametric SSc autoantibody line immunoassay. Material and methods: 158 consecutive patients with SSc (137 females, mean age 53.2 ± 10 years; 63 patients with dcSSc and 95 with lcSSc) from central Greece were included in the study. Eighteen patients with morphea were also included. Serum samples were analyzed by a profile SSc nucleoli line assay (Euroimmun) to detect Abs against 13 autoantigens: Scl-70, Centromere (A, B), RNA polymerase III (subunits 11 & 155), fibrillarin, NOR90, Th/To, PM/Scl 100, PM/Scl75, Ku, PDGFR and Ro52. Antinuclear autoAbs (ANAs) were detected by indirect immunofluorescence. Results: ANAs were detected in 97.5% of SSc patients. Reactivities to specific autoantigens were as follows: Topo I, 40.5%; CENP, 32.9%; Ro52, 21.5%; RP11, 8.9%; RP155, 13.3%; NOR 90, 4.4%; Ku 3.8%; PM-Scl75, 3.2%; PM-Scl100, 1.3%; Th/To, 1.3%; Fibrillarin, 1.3%; PDGFR 0%; Ro52 21.5%. Twenty-one of SSc did not have any of the main autoAbs, namely anti-Topo I, anti-CENP, anti-RNA pol III Abs. Conclusions: Multiparametric autoAb test provides positive SSc-associated autoAb reactivities in SSc patients negative for the three main autoAbs and this may prove of significance in early disease diagnosis. © Liaskos C, Marou E, Simopoulou T, Gkoutzourelas A, Barmakoudi M, Efthymiou G.en
dc.language.isoenen
dc.sourceMediterranean Journal of Rheumatologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85087961228&doi=10.31138%2fmjr.29.3.120&partnerID=40&md5=53dd80846730280407546ce5961636b0
dc.subjectautoantibodyen
dc.subjectautoantigenen
dc.subjectcentromere protein Aen
dc.subjectcentromere protein Ben
dc.subjectDNA directed RNA polymerase IIIen
dc.subjectDNA topoisomeraseen
dc.subjectfibrillarinen
dc.subjectplatelet derived growth factor receptoren
dc.subjectscl 70 antibodyen
dc.subjectadulten
dc.subjectageden
dc.subjectArticleen
dc.subjectblood samplingen
dc.subjectclinical featureen
dc.subjectdisease durationen
dc.subjectfemaleen
dc.subjectGreeceen
dc.subjecthumanen
dc.subjectimmunoassayen
dc.subjectimmunofluorescenceen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmorpheaen
dc.subjectsystemic sclerosisen
dc.subjectGreek Rheumatology Society and Professional Association of Rheumatologistsen
dc.titleMultiparametric autoantibody profiling of patients with systemic sclerosis in Greeceen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής